Protagonist Therapeutics, Inc (PTGX) is a publicly traded Healthcare sector company. As of July 5, 2026, PTGX trades at $131.62 with a market cap of $8.46B and a P/E ratio of -72.72. PTGX moved +5.22% today. Year to date, PTGX is +50.84%; over the trailing twelve months it is +159.66%. Its 52-week range spans $33.31 to $131.87. Analyst consensus is strong buy with an average price target of $117.78. Rallies surfaces PTGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Protagonist Grants New Hires 14,800 Options at $112.46 and 3,900 RSUs: On June 15, 2026, Protagonist granted inducement awards to three new hires totaling options on 14,800 shares and 3,900 RSUs vesting over four years. The options carry an exercise price equal to the June 15 closing price and were approved by the board’s compensation committee.
| Metric | Value |
|---|---|
| Price | $131.62 |
| Market Cap | $8.46B |
| P/E Ratio | -72.72 |
| EPS | $-1.81 |
| Dividend Yield | 0.00% |
| 52-Week High | $131.87 |
| 52-Week Low | $33.31 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $74.06M |
| Net Income | $-114.71M |
| Gross Margin | 0.00% |
10 analysts cover PTGX: 0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $117.78.